The restructuring of chinese API industry has began

This shows that China's API exports class values need to change, upgrade the product structure of the signal has been issued. This is an international market supply and demand is relatively stable, the two companies have increased awareness of the economic risk of the outcome.According to the analysis, since last year, China imported commodities, vaccines, resveratrol, amino acids and insulin are the main varieties of class, this variety structure in recent years, no significant changes. However, according to Hui-Fang Wu, currently a joint venture has gradually shifted from import agents import of bulk drugs and intermediates, and then processed in the domestic preparations. This shows that some of the imported drugs are to achieve local production.China Pharmaceutical Industry Association of the industry analysis report in 2009, 22 in China's domestic sales of a typical hospital's top 20 pharmaceutical companies, there are foreign companies accounted for 80% background. Sales of imported drugs amounted to 12.34 billion yuan, up 24.6%, an increase of 2 percentage points higher than the previous year. As many multinational companies in China are wholly owned or joint venture to build, many imported varieties of domestic production has been achieved, so the changes in recent years, a great variety of imported drugs: Drug imports in 2009 144 new species, not imported 62 varieties; in 736 imported varieties, 70% of the purchase cost rose varieties hospital, of which 40% of the species for more than 50% increase.Export commodities, antibiotics, vitamins, chia seed, amino acids, organic acids and animal organ extract biochemical export of bulk drugs is the main component species, although the bulk of low value-added products dominated the situation has not changed, but in importance have changed: Over the past three years, exports of organic products has been ranked first, but since last year, its export share has declined, the proportion of biological and chemical products exports increased. In fact, exports account for the dominant class of antibiotics and vitamins with the country's export ranking major export tax rebate incentives related to the current tariff numbers to 29,419,090 antibiotic export tax rebate is still 7%, 15% vitamin.Noteworthy change is quantifiable statistics in typical pharmaceutical raw materials, intermediate single species, the export value of over $ 100 million in 11 varieties, including penicillin industrial salt export has dropped substantially in 2009, the export amount has quit " billions of dollars U.S. Army. " The follow-up may enter the "Legion," the varieties of amoxicillin, ceftriaxone, lysine, etc. Dynamic growth of these species does not come from price increases, but on the number of growth, reflecting the bulk drug industry to the downstream development, structural adjustment of the trend. Although citric acid and 6-APA is still living in "billions of dollars U.S. Army," but also showed a drop in price trends, rose, export value decreased by 6.95% year on year and 9.64%.India's anti-dumping certain extent, promoted the Chinese API industry restructuring. In early 2010, India and the Chinese penicillin industrial salt for 6-APA preliminary anti-dumping, despite its opposition to the downstream formulation businesses, Indian authorities issued a document on the preliminary results to be negative, but the event was to promote the China-related business to the downstream products the extension. Source:http://www.cospcn.com